Stockreport

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment fo [Read more]